We are pleased to share positive topline results from our HELIOS-B Phase 3 study of vutrisiran, an investigational #RNAi therapeutic in development for the treatment of #ATTR#amyloidosis w/ cardiomyopathy. Read the press release: https://t.co/LnxVwYjj6n #RNAiTherapeutics#siRNA
@princetongb Actually, I disagree. The ease of a week v, even a once-a-day pill, in the patient population the drug is targeting for growth, to me, is a better target product profile. Compliance is key.
I recommend watching the full run of play leading up to this and following Palhinha as the ball goes from one side the pitch to the other and then he sees the danger and sprints for it.
Almost expecting David Attenborough to be doing voice over as the prey looked for its target.
Congrats @BoisselStephane & the whole @SparingVision team. Another step forward on the mission to deliver options to patient with ocular disorders, for whom there are no options! #GeneTherapy#Fierce23
✨ Shining bright in the heart of Times Square! ✨
In recognition of being named a 'Fierce 15' company for 2023, @Nasdaq showcased this milestone on the big screen in New York. 🍎
More here: https://t.co/r786kQCdYf
#Fierce23#BeFierce#GenomicMedicines#GeneTherapy
✨ Shining bright in the heart of Times Square! ✨
In recognition of being named a 'Fierce 15' company for 2023, @Nasdaq showcased this milestone on the big screen in New York. 🍎
More here: https://t.co/r786kQCdYf
#Fierce23#BeFierce#GenomicMedicines#GeneTherapy
At Entact, we’re aiming to do an entirely new thing: create medicines that enhance, rather than inhibit, the function of key proteins by harnessing the power of DUBs.
Learn more about this approach from David Komander and our other scientific founders: https://t.co/QRrw8R6h8d
Our gene-independent gene therapy product SPVN20 targets retinitis pigmentosa (RP) as the first indication 👀 Let’s take a closer look…
https://t.co/MbHkliZA1y
August in biotech venture usually sees a lull. Not this year. 🚀 Fewer OOOs, more activity, especially from the UK & Europe. Sign of tighter capital or just more due-diligence time? Thoughts? 🤔 #Biotech#VentureCapital#UKBiotech#EuropeanBiotech"
ICYMI, our SVP of Molecular Discovery Simon Bushell shared the invaluable leadership strategies he’s used to build a thriving R&D team here at Entact Bio.
4️⃣ Essential Team Traits
4️⃣ Ways to Foster a Team
Check out his #biotech#teambuilding insights 👇
https://t.co/wyAPRu3sPE
We are excited to kick off Entact's #EmployeeSpotlight series by highlighting Elma Kadic, an Associate Director in our Biological Sciences division. Throughout her career, Elma has identified powerful new technologies and applied them across the drug-discovery continuum.
Excited to be in Paris for a @sparingvision board meeting this week! A privilege to spend time with such an amazing team with brilliant minds using cutting-edge science to create a brighter future for ocular health. #SparingVision#Biotech#GeneTherapy
Great to see @4biocapital portfolio company, Ray Therapeutics, $100m Series A covered today In the WSJ alongside another, SparingVision, who are now enrolling patients in their clinical study of SPVN06! #GeneTherapy#ASGCT
Ray Therapeutics has just landed $100 million to attack retinitis pigmentosa, with a focus on people who have lost their vision. https://t.co/mpHcWfUpJc
Excited to be heading to #ASGCT this week. A few days out of the trenches and taking in the plus from across the sector and sharing portfolio company updates!
In the @PharmaScripAsks Series Part 5 I spoke about innovation in manufacturing and delivery, and what I expect to see in 2023. Read the full article here: https://t.co/6iWJMLLsPe #Fund#Biopharma#Manufacturing#Therapies#innovation
This week I presented at @LINKJEN3’s Advanced Therapy Showcase in Tokyo#3 (ATST#3). It was a pleasure to be invited to present once again and I am proud to have participated since the first #ATST 3 years ago. More: https://t.co/yt9xoDcZER
Just wrapped up a fantastic JPMorgan conference in SF! Great insights, engaging discussions, and valuable networking opportunities. #JPMorgan#SanFrancisco#Biotech#JPM2023